-
Company Insights
Royal Bank of Canada – Digital Transformation Strategies
RBC Digital Transformation Strategies Report Overview Royal Bank of Canada (RBC) has been focusing on using artificial intelligence, machine learning, cloud, big data, and blockchain to digitally transform its operations. The annual ICT spending of RBC was estimated at $725.1 million for 2023. A major share of this spending is earmarked for acquiring software, consulting, and hardware from vendors. RBC is a multinational financial institution providing personal and business banking, wealth management, and institutional banking services. The personal and business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Leiomyosarcoma Drug Details: AZD-1390 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Soft Tissue Sarcoma Drug Details: AZD-1390 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Fibrosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Fibrosarcoma Drug Details: AZD-1390 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMP-9064 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMP-9064 in Solid Tumor report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Sector Analysis
Malaysia Cards and Payments – Opportunities and Risks to 2027
Malaysia Cards and Payments Market Report Overview The annual value of card transactions in the Malaysia cards and payments market is estimated to be $84.5 billion in 2023 and is expected to grow at a CAGR of more than 10% during 2023-2027. The Malaysian payments market remains cash-reliant but has high growth potential as it shifts towards digital payments. Government initiatives including the introduction of an interchange fee cap, the migration of payment cards to support contactless payments, charges on...